Synthesis and structure-activity relationships of 7-substituted 3-(2,6-dichlorophenyl)-1,6-naphthyridin-2(1H)-ones as selective inhibitors of pp60(c-src)

Journal of Medicinal Chemistry

Volumn 43, Issue 16, 2000, Pages 3134-3147

  Thompson, A M ^a   Rewcastle, G W ^a   Boushelle, S L ^b   Hartl, B G ^b   Kraker, A J ^b   Lu, G H ^b   Batley, B L ^b   Panek, R L ^b   Hollis Showalter, H D ^b   Denny, W A ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2,6 DICHLOROPHEYL) 1,6 NAPHTHYRIDIN 2(1H) ONE DERIVATIVE; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR; NAPHTHYRIDINE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE P60; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; IC 50; NONHUMAN; PROTEIN PHOSPHORYLATION; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; CELLS, CULTURED; ENZYME INHIBITORS; HUMANS; MICE; MUSCLE, SMOOTH, VASCULAR; NAPHTHYRIDINES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS PP60(C-SRC); RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RECEPTORS, FIBROBLAST GROWTH FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0034632750     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm000148t     Document Type: Article

References (49)

1. Src expression in small-cell lung carcinomas and other neuroendocrine malignancies
2. pp60(c-src) Activation in human colon carcinoma
3. Differential pp60(c-src) activity in well and poorly differentiated human colon carcinomas and cell lines
4. Expression of pp60(c-src) in human small cell and nonsmall cell lung carcinomas
5. Increased pp60(c-src) tyrosyl kinase activity in human neuroblastomas is associated with amino-terminal tyrosine phosphorylation of the src gene product
6. Characterization of protein tyrosine kinases from human breast cancer: Involvement of the c-src oncogene product
7. SRC as a target for anti-cancer drugs
8. Three-dimensional structure of the tyrosine kinase c-Src
9. Small molecule inhibitors of the platelet-derived growth factor receptor, the fibroblast growth factor receptor and Src family tyrosine kinases
10. Use and selectivity of herbimycin A as inhibitor of protein-tyrosine kinases
11. Identification of tricyclic analogues related to ellagic acid as potent/selective tyrosine protein kinase inhibitors
12. Selective inhibition of the tyrosine kinase pp60(src) by analogues of 5,10-dihydropyrimido[4,5-b]quinolin-4(1H)-one
13. Discovery of a novel, potent, and Src family selective tyrosine kinase inhibitor
14. Pyrrolo[2,3-d]pyrimidines as inhibitors of pp60(c-src)
15. Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibiters
16. Inhibition of src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest
17. Discovery and structure - Activity studies of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors
18. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor
19. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. Structure - activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity
20. A one-step synthesis of 2,4-bis(sec-alkylamino)-6-halo-3-pyridinecarbonitriles
21. Preparation of 6-aryl pyrido[2,3-d]pyrimidines and naphthyridines for inhibiting protein tyrosine kinase-mediated cellular proliferation. WO 9615128, 1996
22. Reduction of hindered nitriles to aldehydes
23. The preparation of Raney nickel catalysts and their use under conditions comparable with those for platinum and palladium catalysts
24. 2-Amino-3-substituted 1,6-naphthyridines
25. Synthesis of 7-substituted 3-aryl-1,6-naphthyridin-2-amines and 7-substituted 3-aryl-1,6-naphthyridin-2(1H)-ones via diazotization of 3-aryl-1,6-naphthyridine-2,7-diamines
26. Thiocyanation of p-dialkylaminoalkoxyanilines
27. Studies on antidiabetic agents. II. Synthesis of 5-[4-(1-methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione (ADD-3878) and its derivatives
28. 11H-Isoindolo[2,1-α]indol-11-ones: Novel rearrangement products from the attempted preparation of 2-(2-diethylaminomethylphenyl)isatogens
29. Synthesis and action of local anesthetics derived from procaine
30. Hydrocupreine aminoalkyl ethers
31. Synthetic analgesics: Piperazine analogues of 6-(dimethylamino)-4,4-diphenylheptan-3-one ('methadone')
32. Unsymmetrically substituted piperazines
33. Ethylenimine-2-carbanilides and isomeric 3-pyridazolidones thereof
34. Addition reactions of 1-cyano-1,3-butadiene
35. Some derivatives of benzo[h]quinoline
36. A general approach to the synthesis of 1,6-, 1,7-, and 1,8-naphthyridines
37. 1,8-Naphthyridines. Part I. Synthesis of some trifluoromethyl-1,8-naphthyridine derivatives
38. Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors
39. Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor
40. A general method for the synthesis of N,N-dialkylaminobutylamines
41. 9-Substituted acridines. Br. Patent 997,036, 1965
42. Quinone imides. X. Addition of amines to p-quinonedibenzenesulfonimide
43. Syntheses of antipyrenic analgesics. VI. N,N-dimethyl-2-(ethoxycarbonyl- and -dialkylcarbamoylanilino)alkanamides
44. Antiulcer agents. 3. Structure-activity-toxicity relationships of substituted imidazo[1,2-α]pyridines and a related imidazo[1,2-α]pyrazine
45. Regiospecific electrophilic substitution of aminopyridines: Ortho lithiation of 2-, 3-, and 4-(pivaloylamino)pyridines
46. A simple method for the protection of arylamines as their tert-butylcarbamoyl (Boc) derivatives
47. Platelet-derived growth factor receptors expressed by cDNA transfection couple to a diverse group of cellular responses associated with cell proliferation
48. Tyrosine kinase inhibitors. 2. Synthesis of 2,2'-dithiobis(1H-indole-3-alkanamides) and investigation of their inhibitory activity against epidermal growth factor receptor and pp60(v-src) protein tyrosine kinases
49. The smooth muscle cell. II. Growth of smooth muscle in culture and formation of elastic fibers